NCT03206918 - Efficacy and Safety of Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 9, 2017

Primary Completion Date

June 15, 2018

Study Completion Date

September 10, 2020

Conditions

Relapsed or Refractory Chronic Lymphocytic LeukemiaRelapsed or Refractory Small Lymphocytic Lymphoma

Interventions

DRUG

Zanubrutinib

Zanubrutinib 160 mg (two - 80 mg white opaque capsules) taken by mouth (PO) twice a day (BID)

Trial Locations (11)

Peking University Peoples Hospital, Beijing

Peking Union Medical College Hospital, Beijing

The First Hospital of Jilin University, Changchun

Jiangsu Province Hospital, Nanjing

The First Affiliated Hospital of Soochow University, Suzhou

Institute of Hematology and Hospital of Blood Disease, Tianjin

Fujian Medical University Union Hospital, Fuzhou

Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology, Wuhan

Henan Cancer Hospital, Zhengzhou

Nanfang Hospital of Southern Medical University, Guangzhou

West China Hospital, Sichuan University, Chengdu